Inova Research Studies: Active/Enrolling - Inova Health System
Inova Research Studies: Active/Enrolling - Inova Health System
Inova Research Studies: Active/Enrolling - Inova Health System
You also want an ePaper? Increase the reach of your titles
YUMPU automatically turns print PDFs into web optimized ePapers that Google loves.
Program -<br />
Principal Investigator<br />
Study Title<br />
Contact<br />
Principal Investigator<br />
Study Title<br />
Contact<br />
Principal Investigator<br />
Study Title<br />
Contact<br />
Principal Investigator<br />
Study Title<br />
Contact<br />
Principal Investigator<br />
Study Title<br />
Contact<br />
Principal Investigator<br />
Study Title<br />
Contact<br />
Center for Liver Diseases<br />
Younossi, Zobair MD<br />
Melanogenesis in Human Adipose Tissue as Possible Drug Target for the Secondary<br />
Complications of Obesity<br />
Younossi, Zobair MD<br />
GS-US-227-0106: A Phase 2b, Double-blind, Randomized, Parallel-Group, Placebo-<br />
Controlled Study to Evaluate the Safety, Tolerability and Efficacy of GS-9450 in Adults<br />
with Chronic Hepatitis C Virus Infection<br />
Heshaam Mir, 703-776-4171, heshaam.mir@inova.org<br />
Younossi, Zobair MD<br />
Resolution of Type 2 Diabetes after Bariatric Surgery<br />
Younossi, Zobair MD<br />
URSO<br />
Heshaam Mir, 703-776-4171, heshaam.mir@inova.org<br />
Younossi, Zobair MD<br />
PGI_02: A multi-center research study of genetic signatures associated with response of<br />
HCV-positive patients to treatment with interferon-alpha and ribavirin<br />
Heshaam Mir, 703-776-4171, heshaam.mir@inova.org<br />
Younossi, Zobair MD<br />
SELECT-2: Phase 2B, Partially Blinded, Randomized Study In Treatment Naïve Subjects<br />
With HCV Genotype 1 To Compare The Efficacy, Safety, And Tolerability Of Three<br />
Doses of LoctEron Plus Ribavirin Given Bi-weekly In Comparison WiTh PEG-Intron Pl<br />
Heshaam Mir, 703-776-4171, heshaam.mir@inova.org<br />
1/18/2010 Page 16 of 64
Change language